School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Cancer. 2021 Mar 15;127(6):957-967. doi: 10.1002/cncr.33329. Epub 2020 Nov 20.
To the authors' knowledge, it is unknown whether patient-reported symptom severity and symptom interference with daily activities differ between younger (aged <65 years) and older (aged ≥65 years) women receiving similar chemotherapy regimens for early breast cancer (EBC).
Study participants rated 17 side effects of chemotherapy regimens currently in use in clinical practice (2014-2019).
Of 284 women with EBC (stage I-III), approximately 57% were aged <65 years and 43% were aged ≥65 years. For anthracycline-based regimens, a higher percentage of younger women reported moderate, severe, or very severe (MSVS) hot flashes (49% vs 18%) (P < .001). For nonanthracycline regimens, a higher percentage of younger women reported MSVS hot flashes (38% vs 19%) (P = .009) and a lower percentage reported MSVS arthralgia (28% vs 49%) (P = .005). With regard to symptom interference with daily activities, a higher percentage of younger women being treated with anthracycline-based regimens reported MSVS hot flashes (32% vs 7%) (P = .001) and myalgia (38% vs 18%) (P = .02). For nonanthracycline chemotherapy, a higher percentage of younger women reported MSVS interference for hot flashes (26% vs 9%) (P = .006) and lower percentages reported abdominal pain (13% vs 28%) (P = .02). Overall, there were no significant differences noted among younger versus older patients with regard to hospitalizations (19% vs 12%; P = .19), dose reductions (34% vs 31%; P = .50), dose delays (22% vs 25%; P = .59), or early treatment discontinuation (16% vs 16%; P = .9546).
Older and younger women with EBC who were treated with identical chemotherapy regimens generally experienced similar levels of symptom severity, symptom-related interference with daily activities, and adverse events.
In this study, women receiving chemotherapy for early breast cancer rated the severity of 17 symptoms and symptom interference with their activities of daily living. Older (aged ≥65 years) and younger (aged <65 years) women who received identical chemotherapy regimens generally experienced similar levels of symptom severity, symptom-related interference with daily activities, and adverse events.
据作者所知，目前尚不清楚接受相似化疗方案治疗早期乳腺癌（EBC）的年轻（<65 岁）和老年（≥65 岁）女性之间，患者报告的症状严重程度和症状对日常生活的干扰是否存在差异。
研究参与者评估了当前临床实践中使用的 17 种化疗方案的副作用。
在 284 例 EBC（Ⅰ-Ⅲ 期）患者中，约 57%的年龄<65 岁，43%的年龄≥65 岁。对于基于蒽环类的方案，更多的年轻女性报告中度、重度或非常重度（MSVS）热潮红（49%对 18%）（P<.001）。对于非蒽环类方案，更多的年轻女性报告 MSVS 热潮红（38%对 19%）（P=.009）和更低的 MSVS 关节痛报告率（28%对 49%）（P=.005）。关于症状对日常生活的干扰，接受基于蒽环类方案治疗的年轻女性中有更高比例报告 MSVS 热潮红（32%对 7%）（P=.001）和肌痛（38%对 18%）（P=.02）。对于非蒽环类化疗，更多的年轻女性报告 MSVS 热潮红（26%对 9%）（P=.006）和较低的腹痛报告率（13%对 28%）（P=.02）。总体而言，在因治疗而住院（19%对 12%；P=.19）、剂量减少（34%对 31%；P=.50）、剂量延迟（22%对 25%；P=.59）或提前停止治疗（16%对 16%；P=.9546）方面，年轻患者与老年患者之间没有显著差异。
接受相同化疗方案治疗的 EBC 年轻和老年女性通常经历相似的症状严重程度、症状相关的日常生活活动干扰和不良事件。
“symptom interference with daily activities”翻译为“症状对日常生活的干扰”，而不是“日常活动中的症状干扰”。
“aged <65 years”翻译为“年龄<65 岁”，“aged ≥65 years”翻译为“年龄≥65 岁”。
“myalgia”翻译为“肌痛”，“arthralgia”翻译为“关节痛”。
“chemotherapy regimens”翻译为“化疗方案”，“regimens”在此处翻译为“方案”比“药物”更合适。
“P <.001”翻译为“P<.001”，“P =.006”翻译为“P=.006”。
“symptom severity”翻译为“症状严重程度”，“adverse events”翻译为“不良事件”。
